Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience

Rosanna Scimè, Anna M. Cavallaro, Alessandra Santoro, Stefania Tringali, Alessandro Indovina, Raimondo Marcenö, Maria Pagano, Daniela Polizzi, Ignazio Majolino

Research output: Contribution to journalArticlepeer-review


Allogeneic transplantation is a potentially curative treatment for most hematological diseases, but its use is still associated with a high regimen related toxicity. Recently regimens with reduced toxicity have been employed.We report here our experience in 12 patients (7 male,5 female) with advanced hematological ( 11 ) or non-hematological(N=l)malignancies, who were treated with a non myeloablative regimen and sibling donor HLA compatible PBSC graft. Median age was 40 yfrange 14-62). Diagnoses were the following: 3 ALL, 2 AML, 2 HD, 1 CML, 1 MDS.l MM, 1 NHD.l breast cancer. Most have been heavly pretreated: 5 were previously allografted and 4 autografted. Disease status at transplant was: I PR, 6 relapses, 2 PD, 1 refractory, 2 CR. As conditioning nine pts received thiotepa (TT) 5 rag/kg and fludarabine (FAMP) 25 mg/m2 x 5 days, 2 patients received FAMP at the same dosage with Ara-C 2 g/m2 x 6 doses, 1 received TT 5 mg/kg and CY 100 mg/kg. All patients received unmanipulated PBSC with a median of 10.4 x 10e6/kg CD34+ (range 221.7). CSA alone 2.5 mg/kg was employed as GVHD prophylaxis. Median time with ANC

Original languageEnglish
Issue number11 PART II
Publication statusPublished - 2000

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Hemopoietic stem cell allogeneic transplantation (HSCT)using a reduced conditioning regimen: A single centre experience'. Together they form a unique fingerprint.

Cite this